

# Innovation Brief

## Non-Imaging Vibration Controlled Ultrasound System - Fibroscan, Supplied by Echosens

### Summary

#### Disruptive innovation

This briefing introduces a disruptive innovation newly available via NHS Supply Chain: The Fibroscan. Reviewed by clinical specialists and supported by key stakeholders, this device offers a novel approach to managing fibrosis and damage to the liver.

### Introduction

This document is intended to inform clinical stakeholders and procurement teams about innovative products that have undergone a clinical review and are now accessible through NHS Supply Chain.

Products featured in this brief may be classified as:

- Disruptive innovations
  - A disruptive innovation is novel.
  - It should offer improvements compared to the existing provision of care.
  - The proposed format should not exist elsewhere (either within or beyond the health and care sector).

**Note:** While robust evidence or validated savings may not yet be available, early data and clinical insights support the potential for patient and system-level improvements.

### Departments / stakeholders for engagement

- NHS procurement teams
- Primary care
- Secondary care
- Community Diagnostic Centres (CDCs)
- Hepatology departments
- Drug and alcohol services

### Opportunity

The Fibroscan presents an opportunity to enhance at risk patient care by:

- Lowering wait times (the Fibroscan does not require a trained sonographer to operate the system).
- Proactively diagnose any potential warning signs of liver damage, therefore allowing patients to make informed steps to improve their lifestyle.
- Relocating scans to community settings to improve attendance (in line with the NHS 10-year plan).
- “Reduce health inequalities for people from underserved groups (such as disabled people, people living in rural areas or people from lower socioeconomic backgrounds)” (DG48 Guidelines).

# Innovation Brief

## Product overview



The Fibroscan is an ultrasound that non-invasively measures the health of a patient's liver. Using transient elastography, the Fibroscan can instantly measure the stiffness of a liver to assist the diagnosis of scarring, fibrosis or cirrhosis and liver disease.

### Clinical relevance:

- A sonographer is not required to use the system.
- Practitioners will receive training from Echosens during the installation of the system.

### Additional benefits:

- The Fibroscan can also help scan for further liver conditions, such as:
  - Hepatitis B
  - Hepatitis C
  - Alcohol-Liver disease
  - Non-Alcoholic Steatohepatitis
  - Non-Alcoholic Fatty Liver Disease (NAFLD)
- Can be used in the community with a small tablet version also available.

### Pathway change:

- Ability to reroute patients to GPs and Community Diagnostic Centres (CDCs) rather than straight to hospitals for a liver biopsy

## Supply details

### MPCs:

- K630E01 (Fibroscan 630 Expert)
- K43M24 (Fibroscan 430 Mini)

### Route - **Direct**

Supplier - Echosens

Brand - Echosens

Unit of Issue - Each

Class IIa Medical Device

## Supporting evidence / notes

- “Reduce health inequalities for people from underserved groups (such as disabled people, people living in rural areas or people from lower socioeconomic backgrounds)” (DG48 Guidelines)

## Contact Details

**Simon Ball** - Clinical Specialist  
[simon.ball@supplychain.nhs.uk](mailto:simon.ball@supplychain.nhs.uk)

**Care Pathway Team** - first point of contact  
[cpt.vbhinquiries@supplychain.nhs.uk](mailto:cpt.vbhinquiries@supplychain.nhs.uk)

**Paris Lowcock** - Category Manager  
[paris.lowcock@supplychain.nhs.uk](mailto:paris.lowcock@supplychain.nhs.uk)

**Ameera Rehman** - Category Buyer  
[ameera.rehman@supplychain.nhs.uk](mailto:ameera.rehman@supplychain.nhs.uk)